Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Proposes 27,000-Patient Observational Trial As Follow-up for Male Use of Gardasil

This article was originally published in The Pink Sheet Daily

Executive Summary

Extension of vaccine to 9-15 year-old boys to prevent genital warts receives lopsided FDA advisory committee votes but some questions about postmarketing studies and duration of effect.

You may also be interested in...

Merck Looks To Mid-June FDA Decision On Expanded Use Of Gardasil To Older Women

Company unveils data at European conference supporting use in women ages 27 through 45; data was sent to FDA late last year.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts